Ovarian cancer can be cured, but the likelihood depends heavily on when it’s caught and how completely it can be removed with surgery. When the cancer is still confined to the ovary, the five-year survival rate is nearly 92%, and long-term data show that about 84% of stage I patients are still alive at 10 years. For advanced-stage disease, a cure is harder to achieve but not impossible.
What “Cured” Actually Means
Oncologists don’t typically use the word “cured” lightly with ovarian cancer. Instead, you’ll often hear “no evidence of disease” or “complete remission.” But researchers have tried to pin down when remission effectively becomes a cure. A multicenter study published in Cancers found that patients who remained disease-free for four years after achieving a complete response almost never relapsed after that point, regardless of how many times their cancer had recurred before. That four-year disease-free mark is the closest thing to a working definition of cure in ovarian cancer.
This is an important distinction. If you or someone you know has been in remission for several years, the odds of the cancer returning drop significantly with each passing year. At a certain point, the risk becomes so small that the disease is functionally gone for good.
Survival Rates by Stage
Stage at diagnosis is the single biggest factor in whether ovarian cancer can be cured. National Cancer Institute data from 2016 to 2022 break it down clearly:
- Localized (confined to the ovary): 91.9% five-year survival
- Regional (spread to nearby lymph nodes or tissues): 70.1% five-year survival
- Distant (spread to other organs): 31.5% five-year survival
Ten-year survival figures tell a fuller story. A study of epithelial ovarian cancer (the most common type) found 10-year relative survival rates of 84% for stage I, 59% for stage II, 23% for stage III, and 8% for stage IV. The stage III number is actually higher than many people expect, and researchers noted it provides more optimistic prognostic information than previously assumed.
The problem is that most ovarian cancers are not caught early. Symptoms like bloating, pelvic pain, and feeling full quickly are vague and easy to dismiss, so the majority of cases are diagnosed at stage III or IV.
Why Surgery Matters So Much
The cornerstone of ovarian cancer treatment is cytoreductive surgery, where the goal is to remove every visible trace of tumor. How much cancer is left behind after surgery has a dramatic effect on outcomes. A meta-analysis in BMC Women’s Health found that patients with no residual disease after surgery had a median overall survival of nearly 50 months. That dropped to about 32 months when any visible tumor remained, and to roughly 24 months when leftover tumor measured more than one centimeter.
Patients with residual disease were about twice as likely to die from their cancer compared to those who had complete removal. The relationship was consistent: the more tumor left behind, the worse the prognosis. This is why choosing an experienced gynecologic oncologist and a high-volume surgical center matters so much. The skill of the surgeon directly influences how much cancer can be removed and, by extension, how long you live.
The Role of BRCA Mutations
Not all ovarian cancers behave the same way, and genetic makeup plays a significant role. Patients who carry BRCA1 or BRCA2 mutations actually tend to do better than those without these mutations, which may seem counterintuitive since BRCA mutations increase the risk of developing ovarian cancer in the first place.
The reason is that BRCA-mutated tumors have a harder time repairing their own DNA, which makes them more vulnerable to platinum-based chemotherapy. A meta-analysis found that BRCA2 carriers had the greatest survival advantage, with a 43% lower risk of death compared to non-carriers. BRCA1 carriers had a 27% lower risk of death. These mutations also make patients eligible for a class of drugs called PARP inhibitors, which exploit the same DNA-repair weakness.
How PARP Inhibitors Changed the Landscape
PARP inhibitors are targeted drugs used as maintenance therapy after chemotherapy, designed to keep cancer from returning. Their impact varies significantly depending on the patient’s genetic profile and when in the treatment course they’re used.
The clearest success story comes from the SOLO-1 trial, which tested olaparib in patients with BRCA-mutated ovarian cancer after their initial treatment. At seven years, the median overall survival in the olaparib group still hadn’t been reached, meaning more than half of patients were still alive. In the placebo group, median survival was about 75 months. That’s a substantial, meaningful difference.
For patients with a broader category of DNA-repair problems (called HRD-positive), combining olaparib with another drug called bevacizumab also showed a survival benefit in the PAOLA-1 trial. However, the picture is less encouraging for patients without these genetic features, and for those who’ve already been through multiple rounds of treatment. Several later-line trials found no survival benefit, and some even suggested patients fared slightly worse on PARP inhibitors than on standard chemotherapy. This makes genetic testing of the tumor essential for choosing the right treatment strategy.
Recurrence Is Common in Advanced Stages
Even after successful treatment, ovarian cancer has a high tendency to return. About 25% of early-stage patients will experience a recurrence, while more than 80% of those diagnosed at advanced stages will see their cancer come back. This is the central challenge of the disease, and it’s why ovarian cancer is often described as manageable but difficult to cure at later stages.
Recurrence doesn’t necessarily mean the end of treatment options. Many patients go through several rounds of surgery and chemotherapy over the course of years, and some achieve long-lasting remissions after recurrence. The four-year disease-free benchmark for cure applies even to patients who have recurred multiple times, as long as they eventually reach that sustained remission.
Maintenance Chemotherapy Has Limited Benefit
One approach that has not proven effective is continuing standard chemotherapy after the initial treatment as a way to prevent recurrence. A Cochrane review combining data from multiple trials found no significant difference in three-year, five-year, or 10-year survival between patients who received maintenance chemotherapy and those who were simply observed. Platinum-based drugs, doxorubicin, and paclitaxel all failed to show a clear advantage when used this way. This is distinct from PARP inhibitor maintenance, which works through a different mechanism and does benefit specific patient groups.
Heated Chemotherapy During Surgery
A newer approach involves bathing the abdominal cavity in heated chemotherapy solution immediately after tumor removal, a procedure called HIPEC. A randomized trial of 184 patients with stage III or IV ovarian cancer found that those who received HIPEC had a five-year survival rate of 57.5%, compared to 52.3% in the surgery-only group. The benefit was modest, and the technique is still not standard practice everywhere, but it represents one more tool in the effort to improve long-term outcomes for advanced disease.
What Shapes Your Individual Outlook
Several factors combine to determine whether ovarian cancer can be cured in any individual case. Stage at diagnosis is the most important, followed by the completeness of surgical removal. Tumor genetics, particularly BRCA status and other DNA-repair deficiencies, affect both how well the cancer responds to treatment and which targeted therapies are available. The specific type of ovarian cancer also matters: high-grade serous carcinoma, the most common subtype, behaves differently from rarer forms like clear cell or mucinous tumors.
For early-stage disease, the outlook is genuinely optimistic, with cure rates exceeding 80% at 10 years. For advanced disease, a smaller but real percentage of patients achieve long-term remission that meets the clinical threshold for cure. The treatment landscape has improved meaningfully in the past decade, particularly for patients whose tumors carry specific genetic vulnerabilities.